Dilated Cardiomyopathy Market By Treatment Type (Drug Therapy, Implantable Cardiac Devices, Surgical Interventions); By Drug Class (Beta Blockers, Angiotensin Receptor–Neprilysin Inhibitors (ARNIs), SGLT2 Inhibitors, Other Drug Classes); By Device Type (Implantable Cardioverter Defibrillators (ICDs), Cardiac Resynchronization Therapy (CRT) Devices, Left Ventricular Assist Devices (LVADs)); By Disease Severity (Mild DCM (NYHA Class I–II), Moderate DCM (NYHA Class III), Severe DCM (NYHA Class IV)); By End User (Hospitals, Specialty Cardiology Clinics, Ambulatory Care Centers); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2026–2032

Dilated Cardiomyopathy Market: How Are Advanced Heart Failure Treatments and Cardiac Care Innovations Reshaping Patient Management? – (Updated On: 2nd-Nov-2026)

According to Strategic Market Research, the Global Dilated Cardiomyopathy Market was valued at USD 2.93 billion in 2025 and is projected to reach USD 4.14 billion by 2032, growing at a CAGR of 5.05% during 2026–2032. Dilated cardiomyopathy (DCM) is a serious heart condition that weakens the heart's ability to pump blood. Patients often require long-term medication, cardiac imaging, rhythm monitoring, genetic assessment, and specialist care, creating sustained demand across the treatment pathway.

 

Recent evidence suggests that the potential patient population may be larger than previously recognized. A May 2026 review in Nature Reviews Cardiology estimated that non-ischemic DCM may affect around 1 in 220 people, based on cardiac MRI studies, with prevalence approximately twice as high in men. A separate systematic review reported prevalence ranging from 42.8 to 118.3 cases per 100,000 people across U.S. and Western European studies. Wider use of cardiac imaging and specialist assessment could therefore identify patients who previously remained undiagnosed.

 

The United States represents a substantial treatment population. Research covering 56.8 million people estimated DCM prevalence at 118.33 per 100,000, equivalent to approximately 388,350 people when applied to the 2019 U.S. population. Higher prevalence among men, adults aged 65 and older, and Black Americans identifies important patient groups for ongoing cardiac care. Published literature also commonly reports 5–8 new cases per 100,000 people annually across Europe and North America.

 

Genetic testing is becoming more relevant to DCM care. Recent research indicates that disease-associated genetic variants can be identified in approximately 30%–40% of patients with non-ischemic DCM. Testing can help identify inherited disease and support screening of appropriate family members, expanding demand beyond treatment toward genetic counseling and family-based cardiac assessment.

 

Most diagnosed patients require continuing heart-failure treatment. Current care commonly includes ARNIs, beta-blockers, mineralocorticoid receptor antagonists, SGLT2 inhibitors, ACE inhibitors or ARBs, and diuretics, depending on the patient's condition. Regular medication adjustment, echocardiography, cardiac MRI, ECG testing, and specialist follow-up make DCM a continuing-care market rather than a one-time treatment opportunity.

 

Patients with more advanced disease create additional demand for cardiac devices and specialist procedures. Cardiac resynchronization therapy and implantable cardioverter-defibrillators are used in eligible patients, while severe cases may progress to ventricular assist devices or heart transplantation. DCM remains particularly important in transplantation: the 2025 ISHLT report recorded DCM in 32.4% of pediatric heart-transplant recipients in 2023, while non-ischemic cardiomyopathy represented 46.8% of adult recipients.

 

New drug development could gradually broaden the treatment landscape. A 2025 phase 2 study of danicamtiv enrolled 41 patients and reported encouraging early findings in cardiac function, including selected genetic subgroups. The KINSHIP-DCM phase 2/3 trial began in February 2026 and is targeting approximately 332 participants. Danicamtiv remains investigational, but the program highlights growing interest in therapies developed specifically for DCM rather than relying entirely on broader heart-failure treatment.

 

Overall, the market's progression from USD 2.93 billion in 2025 to USD 4.14 billion by 2032 is supported by a sizeable diagnosed population, wider cardiac imaging and genetic assessment, long-term use of heart-failure medicines, and continuing demand for cardiac devices and advanced care. Emerging DCM-specific therapies could add another treatment option if ongoing clinical trials demonstrate meaningful benefit.

 

Dilated Cardiomyopathy Market: Which Segments Lead Treatment Expenditure and Which Are Emerging as the Fastest-Expanding Opportunities?

By Treatment Type: Drug Therapy Leads, While Long-Term Pharmacological Management Sustains Market Expansion

Leading Segment – Drug Therapy: Drug therapy dominates the Dilated Cardiomyopathy Market with an estimated 63% share, representing USD 1.846 billion in 2025 revenue, and is projected to register a CAGR of 5.25% during 2026–2032. Its leading position reflects the continuous use of guideline-directed medications, including beta blockers, ARNIs, SGLT2 inhibitors, and other heart failure therapies. Patients frequently receive multiple complementary drug classes, creating recurring prescription revenue. Drug therapy also has the highest projected CAGR among the three treatment categories, supported by treatment intensification, improved diagnosis, and sustained medication use among clinically eligible patients.

 

By Drug Class: ARNIs Lead Revenue, While SGLT2 Inhibitors Offer the Strongest Expansion Potential

Leading Segment – Angiotensin Receptor–Neprilysin Inhibitors (ARNIs): Angiotensin Receptor–Neprilysin Inhibitors (ARNIs) represent the largest individual drug class in the Dilated Cardiomyopathy Market, accounting for an estimated 30% share, equivalent to USD 0.554 billion in 2025, with a projected CAGR of 5.40% during 2026–2032. Sacubitril/valsartan plays a central role in guideline-directed medical therapy (GDMT) for patients with dilated cardiomyopathy presenting with heart failure with reduced ejection fraction (HFrEF). Its established clinical benefits in reducing heart failure hospitalizations and cardiovascular mortality support its continued use in eligible patients.

Fastest-Growing Segment – SGLT2 Inhibitors: SGLT2 inhibitors account for approximately 24% of the Dilated Cardiomyopathy Market's drug therapy revenue, valued at USD 0.443 billion in 2025, and are projected to register the fastest CAGR of 7.00% during 2026–2032. Medications such as empagliflozin and dapagliflozin play an important role in managing dilated cardiomyopathy, particularly among patients experiencing heart failure with reduced ejection fraction (HFrEF). Their ability to reduce heart failure hospitalizations and improve cardiovascular outcomes supports wider clinical adoption alongside established heart failure treatments.

 

By Device Type: ICDs Maintain Revenue Leadership, While CRT Devices Gain Clinical Importance

Leading Segment – Implantable Cardioverter Defibrillators (ICDs): Implantable Cardioverter-Defibrillators (ICDs) account for approximately 46% of implantable cardiac device revenue in the Dilated Cardiomyopathy Market, representing USD 0.404 billion in 2025, with a projected CAGR of 4.20% during 2026–2032. ICDs are small, battery-powered devices implanted in the chest to monitor abnormal heart rhythms and deliver corrective pacing or electrical shocks. In patients with dilated cardiomyopathy (DCM), where an enlarged and weakened heart increases the risk of life-threatening ventricular arrhythmias, ICDs help prevent sudden cardiac death and support long-term cardiac care.

Fastest-Growing Segment – Cardiac Resynchronization Therapy (CRT) Devices: Cardiac Resynchronization Therapy (CRT) Devices account for an estimated 38% market share, valued at USD 0.334 billion in 2025, and are projected to register the fastest CAGR of 5.60% during the forecast period. CRT plays an important disease-modifying role in managing dilated cardiomyopathy (DCM) associated with advanced heart failure by improving coordination between ventricular contractions. Its clinical significance is particularly evident among patients with reduced ejection fraction and electrical conduction abnormalities, where treatment can improve cardiac function, reduce heart failure hospitalizations, and support long-term survival.

 

By Disease Severity: Mild DCM Accounts for the Largest Revenue Pool, While Severe Cases Generate Higher Treatment Intensity

Leading Segment – Mild DCM (NYHA Class I–II): Mild Dilated Cardiomyopathy (DCM) accounts for the largest estimated market share of 44%, valued at USD 1.289 billion in 2025, and is projected to grow at a CAGR of 4.70% during 2026–2032. Mild DCM, generally associated with NYHA Class I–II, represents an early or well-compensated stage characterized by left ventricular enlargement and mild-to-moderate systolic dysfunction. Patients typically experience minimal or no limitations during ordinary physical activity. Early diagnosis, regular cardiac monitoring, and timely medical management remain important in preventing disease progression.

Fastest-Growing Segment – Severe DCM (NYHA Class IV): Severe Dilated Cardiomyopathy (DCM) accounts for approximately 21% of the global market, valued at USD 0.615 billion in 2025, and is projected to register the fastest CAGR of 5.70% during 2026–2032. Severe DCM, particularly NYHA Class IV, represents advanced heart failure characterized by substantial enlargement of the left ventricle and severely impaired cardiac contraction. Patients frequently experience symptoms even at rest, requiring intensive medical management, advanced heart failure therapies, mechanical circulatory support, or heart transplantation in eligible cases.

 

By End User: Hospitals Dominate Treatment Revenue, While Ambulatory Care Centers Expand Outpatient Services

Leading Segment – Hospitals: Hospitals dominate the Dilated Cardiomyopathy Market, accounting for an estimated 70% market share, valued at USD 2.051 billion in 2025, and are projected to grow at a CAGR of 4.80% during 2026–2032. Hospitals play a central role in diagnosing and managing dilated cardiomyopathy through cardiac imaging, medication management, implantable cardiac devices, and advanced heart failure treatment. The availability of specialized cardiology departments, intensive care facilities, and heart transplantation services strengthens their position in treating patients with progressive cardiac dysfunction and severe complications.

Fastest-Growing Segment – Ambulatory Care Centers: Ambulatory Care Centers: Ambulatory care centers accounted for approximately 7% of the Dilated Cardiomyopathy Market, valued at USD 0.205 billion in 2025, and are projected to register the fastest CAGR of 6.10% during the forecast period. Specialized heart failure clinics, outpatient diuresis units, and ambulatory procedural centers support regular cardiac monitoring, medication adjustments, fluid management, and follow-up care for patients with dilated cardiomyopathy. Their expanding role in managing chronic heart failure and reducing avoidable hospital admissions supports continued market growth.

 

By Geography: North America Leads Commercial Activity, While Asia-Pacific Offers the Strongest Regional Expansion

Leading Region – North America: North America accounted for an estimated 39% of the global Dilated Cardiomyopathy Market, valued at USD 1.143 billion in 2025, and is projected to grow at a CAGR of 4.40% during 2026–2032. Clinical management across the United States and Canada follows established heart failure and cardiomyopathy guidelines, supporting the use of guideline-directed medications, implantable cardiac devices, and advanced heart failure therapies. Widespread access to specialized cardiology centers, genetic testing, and cardiac imaging further supports early diagnosis and long-term treatment of dilated cardiomyopathy.

Fastest-Growing Region – Asia-Pacific: Asia-Pacific accounted for an estimated 24% share of the global Dilated Cardiomyopathy Market in 2025, valued at USD 0.703 billion, and is projected to register the fastest regional CAGR of 6.30% during 2026–2032. Dilated cardiomyopathy (DCM), characterized by progressive left ventricular enlargement and impaired cardiac pumping function, is a major contributor to non-ischemic heart failure and heart transplantation across the region. Improving cardiac diagnostic capabilities, expanding access to specialized cardiology services, and increasing treatment availability are supporting regional market expansion.

 

Dilated Cardiomyopathy Market: Which Pharmaceutical Companies Are Strengthening Their Position in Advanced Heart Failure Treatment?

Novartis AG – Established Leadership in ARNI-Based Heart Failure Treatment

Novartis holds an important position in the Dilated Cardiomyopathy Market through Entresto (sacubitril/valsartan), an angiotensin receptor–neprilysin inhibitor used to treat eligible patients with chronic heart failure and reduced ejection fraction, including those with DCM. In the landmark PARADIGM-HF clinical trial involving 8,442 patients, Entresto demonstrated a 20% relative reduction in cardiovascular death or first heart failure hospitalization compared with enalapril. According to Novartis's 2024 annual results, Entresto generated approximately USD 7.8 billion in global sales, demonstrating the commercial significance of ARNI therapy in the wider heart failure market. These figures represent sales across approved indications rather than DCM-specific revenue. Novartis's established cardiovascular treatment portfolio, clinical evidence, and physician adoption support its position in long-term pharmacological management.

AstraZeneca PLC – Expanding Cardiovascular Treatment Through SGLT2 Inhibitors

AstraZeneca is a significant participant in DCM-related heart failure treatment through Farxiga/Forxiga (dapagliflozin), an SGLT2 inhibitor prescribed to eligible patients with heart failure. The DAPA-HF trial enrolled 4,744 patients with heart failure and reduced ejection fraction and demonstrated a 26% relative reduction in worsening heart failure or cardiovascular death compared with placebo. AstraZeneca reported approximately USD 7.7 billion in Farxiga global product sales in 2024, reflecting its substantial presence across cardiovascular, renal, and metabolic indications. These sales are not specific to DCM. The company's cardiovascular and renal treatment strategy supports continued utilization of SGLT2 inhibitors in appropriate DCM patients, particularly where guideline-directed combination therapy is indicated.

Other Important Companies:

• Boehringer Ingelheim: Co-develops and commercializes Jardiance (empagliflozin) with Eli Lilly, supporting heart failure treatment through SGLT2 inhibition and evidence from the EMPEROR clinical trial program.

• Eli Lilly and Company: Partners with Boehringer Ingelheim on Jardiance, contributing to the commercialization of empagliflozin across approved cardiovascular, renal, and metabolic indications.

• Bayer AG: Participates in cardiovascular treatment through Kerendia (finerenone), a nonsteroidal mineralocorticoid receptor antagonist studied in heart failure populations, although it is not a DCM-specific therapy.

• Merck & Co., Inc.: Develops cardiovascular therapies including Verquvo (vericiguat), which has been studied for reducing cardiovascular death and heart failure hospitalization in selected patients with symptomatic chronic heart failure.

 

Emerging Therapies: How Are Targeted Medicines, Gene Therapies, and Regenerative Approaches Transforming Dilated Cardiomyopathy Treatment?

Targeted Small-Molecule and Myosin Modulators

• Danicamtiv: An investigational cardiac myosin activator designed to improve the heart muscle's ability to contract and pump blood. It is being studied as a potential treatment for patients with weakened heart function, including genetic forms of DCM.

• Sarcomeric and Metabolic Modulators: Experimental medicines target abnormalities in heart muscle contraction, cellular energy production, and tissue scarring. These approaches aim to address underlying disease mechanisms and potentially improve cardiac performance.

Gene- and Nucleotide-Based Therapies

• BAG3 Gene Therapy: Investigational gene therapies aim to restore the function of the BAG3 protein, which helps maintain healthy heart muscle cells. Early-stage programs target genetically defined DCM patients, creating opportunities for more personalized treatment.

• LMNA, TTN, and PLN-Targeted Therapies: Gene replacement and RNA-based approaches are being investigated to address inherited mutations associated with DCM. These treatments aim to correct, replace, or reduce the effects of abnormal genetic instructions that weaken the heart muscle.

Regenerative and Cellular Approaches

• Mesenchymal Stem Cell (MSC) Therapy: Experimental stem cell treatments are being studied for their potential to reduce inflammation, limit cardiac tissue damage, and support blood vessel formation through the release of beneficial signaling molecules.

• Induced Pluripotent Stem Cell (iPSC) Technology: Patient-derived stem cells can be converted into heart muscle cells in laboratories, allowing researchers to study genetic abnormalities, evaluate treatment responses, and identify potential therapies tailored to individual patients.

 

Analyst Commentary: How Will Combination Therapy and Specialized Cardiac Care Shape Recurring Revenue?

The Dilated Cardiomyopathy Market is shifting toward earlier diagnosis, guideline-directed combination drug therapy, and more targeted use of implantable cardiac devices. The strongest revenue opportunities lie in expanding ARNI and SGLT2 inhibitor utilization, improving access to ICD and CRT procedures, and advancing treatment options for severe heart failure. Genetic screening, cardiac imaging, and personalized risk assessment are improving treatment selection, while long-term medication requirements, device replacement cycles, and specialized cardiac care continue to support recurring healthcare expenditure.

 

Dilated Cardiomyopathy Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 2.93 Billion
Revenue Forecast in 2032	USD 4.14 Billion
Overall Growth Rate	CAGR of 5.05% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million/Billion, CAGR (2026 – 2032)
Segmentation	By Treatment Type, By Drug Class, By Device Type, By Disease Severity, By End User, By Geography
By Treatment Type	Drug Therapy, Implantable Cardiac Devices, Surgical Interventions
By Drug Class	Beta Blockers, Angiotensin Receptor–Neprilysin Inhibitors (ARNIs), SGLT2 Inhibitors, Other Drug Classes
By Device Type	Implantable Cardioverter Defibrillators (ICDs), Cardiac Resynchronization Therapy (CRT) Devices, Left Ventricular Assist Devices (LVADs)
By Disease Severity	Mild DCM (NYHA Class I–II), Moderate DCM (NYHA Class III), Severe DCM (NYHA Class IV)
By End User	Hospitals, Specialty Cardiology Clinics, Ambulatory Care Centers
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Long-term heart failure medication requirements, adoption of combination drug regimens, use of implantable cardiac devices in eligible patients, improved genetic diagnosis and family screening, clinical development of targeted DCM therapies
Customization Option	Available upon request